Acumen Pharmaceuticals (ABOS) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Acumen Pharmaceuticals (ABOS) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 11.7% versus a loss of 74.8%. Over five years, CMPX leads with a -69.4% price change compared with -84.5% for ABOS. Compass Therapeutics is the larger company by market cap ($177.1 million vs $151.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABOS | CMPX |
|---|---|---|
| Share price | $2.10 | $0.9834 |
| Market cap | $151.87M | $177.10M |
| 1-day change | 0.00% | -3.59% |
| YTD return | -0.47% | -81.69% |
| 1-year return | +11.70% | -74.78% |
| 5-year return | -84.50% | -69.36% |
| EPS (TTM) | $-1.64 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.60 | $6.88 |
| 52-week low | $1.50 | $0.829 |
| Distance from 52-week high | -41.67% | -85.71% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +261.90% | +454.20% |
| Average volume | 439.10K | 4.06M |
| Shares outstanding | 72.32M | 180.09M |
| Employees | 60 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABOS has outperformed CMPX by 86.5 percentage points over the past year.
About Acumen Pharmaceuticals
ABOS stock →Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
ABOS vs CMPX FAQ
Which is bigger, Acumen Pharmaceuticals or Compass Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $177.10M compared with $151.87M for Acumen Pharmaceuticals (ABOS).
Which stock has performed better over the past year, ABOS or CMPX?
ABOS returned +11.70% over the past 12 months, compared with -74.78% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Acumen Pharmaceuticals and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.